866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 101 Pages

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 25 molecules. Out of which approximately 25 molecules are developed by Companies. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 5, 11 and 4 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Ophthalmology and Respiratory which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Autoimmune Disorders, Psoriasis, Vitiligo, Diffuse Large B-Cell Lymphoma, Inflammation, Mantle Cell Lymphoma, Allergic Conjunctivitis, Androgenic Alopecia, Arthritis, Asthma, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Follicular Lymphoma, Heart Transplant Rejection, Inflammatory Bowel Disease, Marginal Zone B-cell Lymphoma, Myeloproliferative Disorders, Peripheral T-Cell Lymphomas (PTCL), Pruritus, Psoriatic Arthritis, Respiratory Tract Inflammatory Disorders, Sarcopenia, Systemic Lupus Erythematosus, Systemic Sclerosis (Scleroderma), Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease) and Waldenstrom Macroglobulinemia.

The latest report Tyrosine Protein Kinase JAK3 - Pipeline Review, H2 2017, outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Overview 8
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Development 9
Products under Development by Stage of Development 9
Products under Development by Therapy Area 10
Products under Development by Indication 11
Products under Development by Companies 14
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Therapeutics Assessment 19
Assessment by Mechanism of Action 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 23
Aclaris Therapeutics Inc 23
Arrien Pharmaceuticals LLC 23
Astellas Pharma Inc 23
Bristol-Myers Squibb Co 24
Chipscreen Biosciences Ltd 24
Clevexel Pharma SAS 25
Japan Tobacco Inc 25
LSK BioPartners Inc 26
Merck & Co Inc 26
MYOS RENS Technology Inc 27
Pfizer Inc 27
Portola Pharmaceuticals Inc 28
Sienna Biopharmaceuticals Inc 29
Simcere Pharmaceutical Group 29
Theravance Biopharma Inc 30
Vectura Group Plc 30
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Drug Profiles 32
ARN-4079 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
ATI-50001 - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ATI-50002 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
ATI-50003 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
cerdulatinib - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
CS-510 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
CS-944X - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CVXL-0074 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
JTE-052 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
KBP-7536 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
LSK-9985 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
OST-122 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
peficitinib hydrobromide - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
PF-06651600 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Inhibit JAK1 and JAK3 for Autoimmune Diseases and Inflammation - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit JAK2 and JAK3 for Oncology and Auto Immune Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Inhibit JAK3 for Rheumatoid Arthritis, Sarcopenia and Cachexia - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
SNA-125 - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
TD-1473 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
TD-3504 - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
tofacitinib citrate - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
VR-588 - Drug Profile 82
Product Description 82
Mechanism Of Action 82
R&D Progress 82
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Dormant Products 83
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Discontinued Products 86
Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Product Development Milestones 87
Featured News & Press Releases 87
Oct 16, 2017: New Ulcerative Colitis Data for XELJANZ (tofacitinib)at Upcoming Gastroenterology Congresses 87
Sep 08, 2017: NICE issues positive recommendation for XELJANZ (tofacitinib citrate) as a new treatment option for adults with severe rheumatoid arthritis 88
Aug 28, 2017: Studies reveal how shingles vaccine should be used in arthritis patients 89
Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 89
Aug 03, 2017: Fda Advisory Committee Votes In Favor Of XELJANZ (Tofacitinib Citrate) For The Treatment Of Active Psoriatic Arthritis 91
Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 91
Jul 13, 2017: Pfizer Announces FDA Accepts Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Moderately To Severely Active Ulcerative Colitis 92
Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 92
Jun 16, 2017: Pfizer Announces Results From XELJANZ (Tofacitinib Citrate) Oral Strategy Study Published In The Lancet And Presented At The EULAR Annual Congress 93
Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 94
May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 95
May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 96
May 05, 2017: Aclaris Therapeutics Completes Phase 1 Clinical Trial of ATI-50001 for the Treatment of Alopecia Universalis and Alopecia Totalis 96
May 03, 2017: Pfizer Announces U.S. FDA Filing Acceptance Of Supplemental New Drug Application For Xeljanz (Tofacitinib Citrate) For The Treatment Of Adult Patients With Active Psoriatic Arthritis 97
May 03, 2017: Phase 3 Octave Studies Of Oral Tofacitinib In Ulcerative Colitis Results Published In The New England Journal Of Medicine 97
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 100
Contact Us 100
Disclaimer 101

List of Tables
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 13
Number of Products under Development by Companies, H2 2017 14
Products under Development by Companies, H2 2017 15
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 16
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 17
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 18
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Stage and Route of Administration, H2 2017 21
Number of Products by Stage and Molecule Type, H2 2017 22
Pipeline by Aclaris Therapeutics Inc, H2 2017 23
Pipeline by Arrien Pharmaceuticals LLC, H2 2017 23
Pipeline by Astellas Pharma Inc, H2 2017 24
Pipeline by Bristol-Myers Squibb Co, H2 2017 24
Pipeline by Chipscreen Biosciences Ltd, H2 2017 25
Pipeline by Clevexel Pharma SAS, H2 2017 25
Pipeline by Japan Tobacco Inc, H2 2017 26
Pipeline by LSK BioPartners Inc, H2 2017 26
Pipeline by Merck & Co Inc, H2 2017 27
Pipeline by MYOS RENS Technology Inc, H2 2017 27
Pipeline by Pfizer Inc, H2 2017 28
Pipeline by Portola Pharmaceuticals Inc, H2 2017 29
Pipeline by Sienna Biopharmaceuticals Inc, H2 2017 29
Pipeline by Simcere Pharmaceutical Group, H2 2017 30
Pipeline by Theravance Biopharma Inc, H2 2017 30
Pipeline by Vectura Group Plc, H2 2017 31
Dormant Products, H2 2017 83
Dormant Products, H2 2017 (Contd..1), H2 2017 84
Dormant Products, H2 2017 (Contd..2), H2 2017 85
Discontinued Products, H2 2017 86

List of Figures
Number of Products under Development by Stage of Development, H2 2017 9
Number of Products under Development by Therapy Areas, H2 2017 10
Number of Products under Development by Indications, H2 2017 11
Number of Products by Stage and Mechanism of Actions, H2 2017 19
Number of Products by Routes of Administration, H2 2017 20
Number of Products by Stage and Routes of Administration, H2 2017 20
Number of Products by Stage and Molecule Type, H2 2017 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *